The estimated Net Worth of Stephen George Dilly is at least $37 million dollars as of 8 September 2023. Dr Dilly owns over 58,479 units of Sierra Oncology Inc stock worth over $24,133,901 and over the last 15 years he sold SRRA stock worth over $12,066,208. In addition, he makes $778,945 as Pres et CEO & Director at Sierra Oncology Inc.
Dr has made over 16 trades of the Sierra Oncology Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 58,479 units of SRRA stock worth $101,169 on 8 September 2023.
The largest trade he's ever made was exercising 165,374 units of Sierra Oncology Inc stock on 1 June 2018 worth over $499,429. On average, Dr trades about 21,870 units every 59 days since 2010. As of 8 September 2023 he still owns at least 438,878 units of Sierra Oncology Inc stock.
You can see the complete history of Dr Dilly stock trades at the bottom of the page.
Dr. Stephen George Dilly M.B.B.S, Ph.D. is the Pres, CEO & Director at Sierra Oncology Inc.
As the Pres et CEO & Director of Sierra Oncology Inc, the total compensation of Dr D at Sierra Oncology Inc is $778,945. There are 3 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.
Dr D is 61, he's been the Pres et CEO & Director of Sierra Oncology Inc since . There are 6 older and 11 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.
Stephen's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth et James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: